Related Experiment Video
Updated: Jun 4, 2026
09:31
Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
Published on: October 2, 2015
Low-dose cyclophosphamide modulates galectin-1 expression and function in an experimental rat lymphoma model.
Mariano F Zacarías Fluck1, María J Rico, Silvia I Gervasoni
1Institute of Experimental Genetics, School of Medical Sciences, National University of Rosario, Santa Fe 3100, 2000 Rosario, Argentina.
Cancer Immunology, Immunotherapy : CII
|May 31, 2006
Summary
Cyclophosphamide (Cy) treatment restrains lymphoma metastasis and modulates Galectin-1 (Gal-1) expression. This immunomodulatory agent impacts Gal-1
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Tumor immunity is influenced by immune escape strategies.
- Galectin-1 (Gal-1) promotes tumor immune evasion by affecting T cells.
- Regulation of Gal-1 in vivo remains poorly understood.
Purpose of the Study:
- To investigate the effect of low-dose cyclophosphamide (Cy) on Gal-1 expression and function.
- To explore the role of Gal-1 in tumor growth, metastasis, and immune response.
- To assess the immunomodulatory potential of Cy in a rat lymphoma model.
Main Methods:
- Administration of low-dose cyclophosphamide (Cy) in the L-TACB rat lymphoma model.
- Time-course analysis of Gal-1 expression in primary tumors, metastasis, and spleen.
- Assessment of T cell survival in response to Gal-1 and Cy treatment.
Main Results:
- Single low-dose Cy restrained metastasis and modulated Gal-1 expression.
- Gal-1 expression correlated positively with primary tumor volume.
- Cy treatment restored basal Gal-1 levels and protected spleen T cells from Gal-1-induced death.
Conclusions:
- Cyclophosphamide (Cy) modulates Galectin-1 (Gal-1) expression and function.
- This modulation has implications for tumor immune escape and immunotherapy.
- Cy exhibits immunomodulatory effects beyond its antimetastatic properties.
